Tigecycline is a broad-spectrum glycylcycline antibiotic that binds to the bacterial 30S ribosome, blocking the entry of transfer RNA, which halts protein synthesis and inhibits bacterial growth.1 It is active against a panel of 1,924 European clinical bacterial isolates including S. aureus, S. epidermidis, S. pneumoniae, E. faecalis, E. faecium, E. coli, K. pneumoniae, P. aeruginosa, and P. mirabilis strains (MICs = <1-32 μg/ml).2 In vivo, tigecycline (6.25 mg/kg twice daily for 5 days) decreases levels of C. difficile cytotoxin activity and spore formation in cecum and colon in a mouse model of C. difficile infection.3 Formulations containing tigecycline have been used in the treatment of a variety of bacterial infections.
1.Greer, N.D.Tigecycline (Tygacil): The first in the glycylcycline class of antibioticsProc. (Bayl. Univ. Med. Cent.)19(2)155-161(2006) 2.Milatovic, D., Schmitz, F.J., Verhoef, J., et al.Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolatesAntimicrob. Agents Chemother.47(1)400-404(2003) 3.Theriot, C.M., Schumacher, C.A., Bassis, C.M., et al.Effects of tigecycline and vancomycin administration on established Clostridium difficile infectionAntimicrob. Agents Chemother.59(3)1596-1604(2015)